YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Mizuho Securities added software company Oracle Corp to its Top Picks list as a No. 1 pick, setting a $320 price target that is 25% above Bloomberg consensus on surging demand for its artificial-intelligence cloud services…
Monday - Lumentum Holdings What's the full story? Evercore initiates Lumentum Lumentum Holdings Inc (NASDAQ:LITE) at Outperform with an $1,100 target. The AI revolution has a supply-chain coronary: silicon processors run fast, but data can…
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Quick Read All major indices closed lower Tuesday as war tensions and rising oil prices drove the Russell 2000 down 1% and Nasdaq down 1%. The 30-year Treasury bond hit 5.27%, its highest yield since 2007, while Brent Crude surged 5% to $9…
Buy Sell cards by Kelly Sikkema via Unsplash Virginia-based conglomerate Graham Holdings (GHC)was one of Barchart's 200 bearish price surprises in Monday trading. It was down 2.2% on the day to $1,165.29; its standard deviation was -1.67,…
EyePoint EYPT announced top-line results from the first of two pivotal late-stage clinical studies evaluating its investigational candidate, Duravyu (vorolanib intravitreal insert), in patients with wet age-related macular degeneration (we…
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as…
September Nasdaq 100 E-Mini futures (NQU26) are down -1.21% this morning as a global bond rout sapped investors' appetite for risk, triggering a selloff in chip and other AI-related stocks. Chip and AI infrastructure stocks were among the…
Fearless Girl looking up at Wall Street at Night by Tim Pruss via iStock The S&P 500 Index ($SPX) (SPY) closed down by -0.52% on Monday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.51%, and the Nasdaq 100 Index ($IUXX)…
Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame. Continue Reading
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate…
Check out some of the companies making the biggest moves midday: Intuitive Machines — Shares of the maker of robotic spacecraft and landers designed to fly to the moon jumped another 9%, rising for a fifth day. Houston-based Intuitive said…
[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCUL […
Inside NYSE by Orhan Akkurt via Shutterstock The S&P 500 Index ($SPX) (SPY) is down by -0.15% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.28%. E-mini S&P futur…
Road sign of New York Wall street corner Broad street by Mezzotint via Shutterstock The S&P 500 Index ($SPX) (SPY) is up by +0.17% today, the Dow Jones Industrial Average ($DOWI) (DIA) is up by +0.20%, and the Nasdaq 100 Index ($IUXX) (QQQ…
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago. These figures are adjusted for non-recurring items. Th…
Wall Street expects a year-over-year decline in earnings on lower revenues when EyePoint (EYPT) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings pictu…
[Black stethoscope and US dollar bills on light blue background] Muhammad Labib Adilah/iStock via Getty Images The U.S. Department of Justice announced on Friday that EyePoint Pharmaceuticals (EYPT [https://seekingalpha.com/symbol/EYPT]) a…
WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announce…
EyePoint, Inc. (NASDAQ:EYPT) is among the best get rich quick stocks to buy right now. Andreas Argyrides, an analyst at Chardan, significantly lifted the price target on EyePoint, Inc. (NASDAQ:EYPT) to $65 from $29 on July 1. Calling the c…
[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]…
Even after its sharp pullback, Space Exploration Technologies' (NASDAQ: SPCX) market cap still hovers around $2 trillion. That's an astronomical (no pun intended) valuation for a company that generated revenue of $18.7 billion last year an…
Key Points Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billionglobal market Viking Therapeutics is on track to give E…
On May 15, 2026, Cormorant Asset Management disclosed a buy of 313,645 shares of Alumis(NASDAQ:ALMS), with the estimated transaction value at $7.84 million based on quarterly average pricing. What happened According to a May 15, 2026 SEC f…
Cormorant Asset Management disclosed a new position in Erasca(NASDAQ:ERAS) in its May 15, 2026, SEC filing, purchasing 5,800,000 shares in a trade estimated at $68.55 million based on quarterly average pricing. What happened According to i…
Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share p…
* EyePoint Pharmaceuticals (EYPT [https://seekingalpha.com/symbol/EYPT]) is scheduled to announce Q1 earnings results on Wednesday, May 6th, before market open. * The consensus EPS Estimate is -$0.81 [https://seekingalpha.com/symbol/EYPT/e…
Arvinas, Inc.ARVN shares soared 6.9% in the last trading session to close at $11.33. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.7% loss over the past fo…
[Lawsuit Gavel] * EyePoint (EYPT [https://seekingalpha.com/symbol/EYPT]) has filed a lawsuit against Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) in a Massachusetts federal court, alleging that its rival eye drug develo…
March 20 (Reuters) - EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug. The complaint was filed in Middlesex County Superio…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. About a dozen biotechnology companies currently stand out as the most likely to receive inter…
Cormorant Asset Management disclosed a buy of 2,361,260 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) in its February 17, 2026 SEC filing, an estimated $27.86 million trade based on quarterly average pricing. What happened According t…
On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx(NASDAQ:ACLX), an estimated $63.63 million transaction based on last-disclosed position values. What happened Accordi…
Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside C…
Cormorant Asset Management initiated a new position in Olema Pharmaceuticals(NASDAQ:OLMA), buying 2,750,000 shares worth $68.75 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened Cormorant Asset Mana…
Key Points Cormorant Asset Management sold 50,000 shares of PRAX in the fourth quarter; the estimated trade size was $9.31 million based on quarterly average pricing. Meanwhile, the quarter-end value of the PRAX position increased by $227.…